Drug resistance is one of the biggest challenges in oncology, accounting for more than 90% of cancer deaths. In this virtual event, key opinion leaders (KOLs) Marc-Steffen Raab (Heidelberg University Hospital) and Jonathan L. Kaufman (Emory University), will discuss recent data of Heidelberg Pharma’s lead candidate, HDP-101, in relapsed or refractory multiple myeloma. Heidelberg Pharma’s approach, which uses Amanitin as a payload, offers a novel mode of action by debulking the tumor and killing cancer stem cells, the key drivers of tumor relapse and metastasis.
Key Highlights:
- HDP-101 is an anti-BCMA antibody-Amanitin drug conjugate, advancing in Cohort 8 of a Phase I/IIa clinical trial in relapsed or refractory multiple myeloma.
- HDP-101 as monotherapy has shown favorable safety and encouraging efficacy, with objective responses including a complete response.
- HDP-101 is well-tolerated with no signs of ocular toxicities, kidney, liver or lung damage, infusion reactions, or extensive myelosuppression.
- Heidelberg Pharma’s approach is distinct, as Amanitin effectively targets both dividing and dormant tumor cells by inhibiting the RNA polymerase II through a cell-cycle independent mechanism. Almost all ADCs in clinical use or development are based on a small number of toxic compounds, largely limited to microtubule- or DNA-targeting toxins that primarily affect proliferating cells.
- Updated clinical data will be presented at the 30th European Hematology Association (EHA) Congress, taking place in Milan from June 12–15, 2025.
Why Attend?
This is a fantastic opportunity to learn more about the treatment landscape in this severe and currently incurable disease. Attendees can participate in a live Q&A session at the end of the presentation or submit questions in advance of the event.
Join us for an informative session that will provide fascinating insights into a novel and under-utilised ADC payload class. Register now to secure your spot!
Webinar Leaders
Jonathan L. Kaufman, MD
David Bankes Glass Professor, Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University
Prof. Dr. med. Marc-Steffen Raab
Director Heidelberg Myeloma Center, Heidelberg University Hospital
You May Also Be Interested In…
Navigating Payload Innovation and Toxicity Trends in ADC Development
Register Now
Learn More About ADC
- The Most Comprehensive Way to Search the ADC Drug Development Landscape: Unique search ontologies based on ADC drug and trial characteristics
- Market Leading Approach to ADC Preclinical & Clinical Data Curation: Manual curation of key ADC research and development data points by ADC research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search ADC company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
